This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Chronic Kidney Disease.
Studies have shown that stem cell treatment is safe and efficacious for the treatment of Chronic Kidney Disease (CKD). This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) for the treatment of CKD. Patients with CKD will receive a single intravenous infusion of UC-MSCs. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy. For patients with more severe disease an autologous Effector cells (activated lymphocytes) treatment will be utilized created from the patient's own cells obtained by apheresis.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Medical Surgical Associates Center
St John's, Antigua and Barbuda
RECRUITINGSafety (adverse events)
Clinical monitoring of possible adverse events or complications
Time frame: Four year follow-up
Efficacy: creatinine levels
It will be completed for each follow up point.
Time frame: Four year follow-up
Efficacy: changes in eGFR
It will be completed for each follow up point.
Time frame: Four year follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.